Studies on new ophthalmic neuroprotective medicinal products (Q3789772)

From EU Knowledge Graph
Revision as of 19:00, 1 February 2022 by DG Regio (talk | contribs) (‎Changed an Item: Adding French translations)
Jump to navigation Jump to search
Project Q3789772 in Lithuania
Language Label Description Also known as
English
Studies on new ophthalmic neuroprotective medicinal products
Project Q3789772 in Lithuania

    Statements

    0 references
    1,263,174.93 Euro
    0 references
    2,027,680.13 Euro
    0 references
    62.3 percent
    0 references
    3 April 2018
    0 references
    31 March 2022
    0 references
    Uždaroji akcinė bendrovė "Profarma"
    0 references
    0 references

    54°37'34.50"N, 25°8'26.59"E
    0 references
    02241
    0 references
    UAB „Profarma“ sukauptos farmacinių baltymų gyvavimo laiko prailginimo žinios gali būti naudojamos prailginant įvairių farmacinių baltymų gyvavimo laiką. MTEP projekto metu planuojama papildomai sukurti ProMer technologija modifikuotus augimo faktorius ir atlikti reikalingus tyrimus. (Lithuanian)
    0 references
    The knowledge accumulated by UAB Profarma to extend the lifespan of pharmaceutical proteins can be used to prolong the lifespan of various pharmaceutical proteins. During the R & D project, it is planned to develop additional growth factors modified by Promer technology and to carry out the necessary studies. (English)
    1 February 2022
    0 references
    Les connaissances accumulées par UAB Profarma pour prolonger la durée de vie des protéines pharmaceutiques peuvent être utilisées pour prolonger la durée de vie de diverses protéines pharmaceutiques. Au cours du projet de R & D, il est prévu de développer des facteurs de croissance supplémentaires modifiés par la technologie Promer et de réaliser les études nécessaires. (French)
    1 February 2022
    0 references
    V. A. Graičiūno g. 6, Vilnius
    0 references

    Identifiers

    J05-LVPA-K-03-0073
    0 references